Surgical oncology: Why biopsying metastatic breast cancer should be routine

Nature Reviews Clinical Oncology

Volumn 7, Issue 2, 2010, Pages 72-74

  Sharma, Anand ^a   Crook, Tim ^a   Thompson, Alastair ^b   Palmieri, Carlo ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; TRASTUZUMAB;

BREAST BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL PRACTICE; DIAGNOSTIC ERROR; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SECOND CANCER; SHORT SURVEY; TUMOR BIOPSY;

BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 76449104031     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.222     Document Type: Short Survey

References (10)

1. Kamangar, F., Dores, G. M. & Anderson, w. F. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24, 2137-2150 (2006).
2. Cardoso, F. et al. Clinical application of the 70-gene profile: the MinDACT trial. J. Clin. Oncol. 26, 729-735 (2008).
3. sparano, J. A. & Paik, s. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26, 721-728 (2008).
4. simmons, C. et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann. Oncol. 20, 1499-1504 (2009).
5. Li, B. D., Byskosh, A., Molteni, A. & Duda, R. B. estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J. Surg. Oncol. 57, 71-77 (1994).
6. wang, B. et al. Discordance of estrogen receptor (eR), progestin receptor (PR), and HeR-2 receptor statuses between primary and metastatic focuses of breast cancer. Ai Zheng. 23, 1710-1713 (2004).
7. Lipton, A. et al. serum HeR-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104, 257-263 (2005).
8. Kuukasjarvi, T., Kononen, J., Helin, H., Holli, K. & isola, J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. Clin. Oncol. 14, 2584-2589 (1996).
9. Liedtke, C. et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann. Oncol. 20, 1953-1958 (2009).
10. weigelt, B. et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 65, 9155-9158 (2005).